Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 3/20 | 0.56 |
| ▸ | FOLH1 | Q04609 | 11/20 | 0.45 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.36 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.35 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.34 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.34 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.34 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20179262 | 0.94 | SLC7A5 (0.49) | SLC7A5FOLH1 | |
| SCHEMBL21570560 | 0.91 | FOLH1 (0.56) | SLC7A5FOLH1 | |
| SCHEMBL20168665 | 0.91 | FOLH1 (0.56) | SLC7A5FOLH1 | |
| SCHEMBL21578063 | 0.86 | SLC7A5 (0.58) | SLC7A5FOLH1LOXL2CYP4F2CYP4A11 | |
| SCHEMBL20179138 | 0.86 | SLC7A5 (0.38) | SLC7A5FOLH1MEN1CYP3A4KMT2A | |
| SCHEMBL20168666 | 0.86 | SLC7A5 (0.38) | SLC7A5FOLH1MEN1CYP3A4KMT2A | |
| SCHEMBL21570577 | 0.85 | FOLH1 (0.49) | SLC7A5FOLH1 | |
| SCHEMBL20168766 | 0.85 | FOLH1 (0.49) | SLC7A5FOLH1 | |
| SCHEMBL20168326 | 0.84 | SLC7A5 (0.61) | SLC7A5FOLH1LOXL2AAK1 | |
| SCHEMBL20179266 | 0.82 | SLC7A5 (0.47) | SLC7A5FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11866394-B2 | Prodrugs of hydroxamate-based GCPII inhibitors | THE JOHNS HOPKINS UNIVERSTY (US) | 2024-01-09 | — | — | US | disclosed |
| US-20210355079-A1 | PRODRUGS OF HYDROXAMATE-BASED GCPII INHIBITORS | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY AS CR V.V.I. (CZ) | 2021-11-18 | — | — | US | disclosed |
| US-11059775-B2 | Prodrug compositions and utility of hydroxamate-based GCPII inhibitors | THE JOHNS HOPKINS UNIVERSITY (US) | 2021-07-13 | — | — | US | disclosed |
| US-20190352255-A1 | NOVEL PRODRUG COMPOSITIONS AND UTILITY OF HYDROXAMATE-BASED GCPII INHIBITORS | THE JOHNS HOPKINS UNIVERSITY | 2019-11-21 | — | — | US | disclosed |
| WO-2018094334-A1 | PRODRUGS OF HYDROXAMATE-BASED GCPII INHIBITORS | THE JOHNS HOPKINS UNIVERSITY (US) | 2018-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190352255-A1 | NOVEL PRODRUG COMPOSITIONS AND UTILITY OF HYDROXAMATE-BASED GCPII INHIBITORS | GPI, TPI1, HPGDS | SLC7A5 505/4885FOLH1 10/4885LOXL2 1675/4885 |
| US-20210355079-A1 | PRODRUGS OF HYDROXAMATE-BASED GCPII INHIBITORS | TPI1, HPGDS, GPI | SLC7A5 463/4885FOLH1 39/4885LOXL2 1853/4885 |
| US-11059775-B2 | Prodrug compositions and utility of hydroxamate-based GCPII inhibitors | GLS, HPGDS, GPI | SLC7A5 536/4885FOLH1 15/4885LOXL2 1774/4885 |
| US-11866394-B2 | Prodrugs of hydroxamate-based GCPII inhibitors | TPI1, HPGDS, GPI | SLC7A5 463/4885FOLH1 39/4885LOXL2 1853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.